Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine-glycopyrrolate Fixed-dose Combination in COPD
NCT07016412Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Merck & Co. Primary endpoint: Average Forced Expiry Volume in 1 Second Area Under the Curve Versus Time From Time 0 to 4 Hours. Started Jul 2025; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07016412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016412.